Physician profile
John Adams
NPI 1639109739
$6,396.97
in general payments reported to CMS, 2019-2025
29 companies · $316 in 2025
The $316 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,956 · 2020: $529 · 2021: $667 · 2022: $1,237 · 2023: $594 · 2024: $1,098 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357 · Travel and Lodging: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.56 |
| Travel and Lodging | $651.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,393.24 | 2019-2025 | Proclaim, Octrode, Eterna |
| Nevro Corp. | $585.36 | 2022-2024 | Senza |
| Collegium Pharmaceutical, INC. | $458.24 | 2019-2025 | Belbuca |
| Boston Scientific Corporation | $372.05 | 2019-2025 | General - Therapies, Wavewriter Alpha Prime 16 |
| Scilex Pharmaceuticals INC. | $357.79 | 2022-2024 | Ztlido |
| Medtronic USA, INC. | $343.62 | 2019 | |
| Nalu Medical, INC. | $156.71 | 2021-2025 | Nalu Neurostimulation System |
| Mdd US Operations, LLC | $125.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $117.43 | 2019 | |
| Glaxosmithkline, LLC. | $54.17 | 2019-2022 | |
| Bioventus LLC | $50.34 | 2024-2025 | Gelsyn-3 |
| Pfizer INC. | $48.36 | 2019 | |
| Globus Medical, INC. | $35.98 | 2025 | Senza |
| Indivior INC. | $34.89 | 2019 | |
| Astellas Pharma US INC | $29.95 | 2025 | Xtandi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $27.04 | 2020 | |
| Stimwave Technologies Incorporated | $23.14 | 2022 | |
| Azurity Pharmaceuticals, INC. | $21.45 | 2023 | Horizant |
| Depuy Synthes Sales INC. | $18.84 | 2022 | |
| Arbor Pharmaceuticals, INC. | $18.35 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.01 | 2025 | Relistor |
| Redhill Biopharma INC. | $15.98 | 2021 | |
| Covidien Lp | $15.26 | 2019 | |
| Curonix LLC | $14.02 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Medtronic, INC. | $13.96 | 2021 | |
| Baudax Bio INC. | $13.13 | 2020 | |
| Horizon Therapeutics Plc | $12.90 | 2022 | |
| Radius Health, INC. | $12.72 | 2019 | |
| Biodelivery Sciences International, INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.